Advanced

Open-Label Trial of Atomoxetine Hydrochloride in Adults With ADHD

Johnson, Mats; Cederlund, Mats; Råstam, Maria LU ; Areskoug, Björn and Gillberg, Christopher (2010) In Journal of Attention Disorders 13(5). p.45-539
Abstract
Background:

While atomoxetine is an established treatment for attention-deficit/hyperactivity disorder in children, few studies have examined its efficacy for adults.



Methods:

Open-label trial of atomoxetine in 20 individuals with ADHD, aged 19-47 years, for 10 weeks, and a total of one year for responders.



Results:

Ten patients met primary efficacy criteria at 10 weeks. Only one patient completed the whole study. Six patients discontinued before 10 weeks and thirteen at 10 weeks or later, mainly because of side-effects (aggression, depressed mood, raised liver enzymes, thyroid hormones, diastolic blood

pressure), decreasing efficacy or non-compliance. ... (More)
Background:

While atomoxetine is an established treatment for attention-deficit/hyperactivity disorder in children, few studies have examined its efficacy for adults.



Methods:

Open-label trial of atomoxetine in 20 individuals with ADHD, aged 19-47 years, for 10 weeks, and a total of one year for responders.



Results:

Ten patients met primary efficacy criteria at 10 weeks. Only one patient completed the whole study. Six patients discontinued before 10 weeks and thirteen at 10 weeks or later, mainly because of side-effects (aggression, depressed mood, raised liver enzymes, thyroid hormones, diastolic blood

pressure), decreasing efficacy or non-compliance.



Conclusion:

Fifty percent responded to treatment, but only one patient (5%) felt sufficient improvement to continue for one year. Dosage may have been too low, and baseline impairment too high, for atomoxetine to have sufficient effect on ADHD symptoms in our group of adults. The majority had few side-effects, but several terminated treatment because of adverse effects. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
long-term trial, adults, atomoxetine, ADHD
in
Journal of Attention Disorders
volume
13
issue
5
pages
45 - 539
publisher
SAGE Publications
external identifiers
  • Scopus:77649247794
ISSN
1557-1246
DOI
10.1177/1087054709332372
language
English
LU publication?
yes
id
c852ce2b-785e-4392-a142-3672f6a360e1 (old id 1457526)
date added to LUP
2011-02-21 17:12:52
date last changed
2016-10-13 04:45:11
@misc{c852ce2b-785e-4392-a142-3672f6a360e1,
  abstract     = {Background: <br/><br>
While atomoxetine is an established treatment for attention-deficit/hyperactivity disorder in children, few studies have examined its efficacy for adults. <br/><br>
<br/><br>
Methods: <br/><br>
Open-label trial of atomoxetine in 20 individuals with ADHD, aged 19-47 years, for 10 weeks, and a total of one year for responders. <br/><br>
<br/><br>
Results: <br/><br>
Ten patients met primary efficacy criteria at 10 weeks. Only one patient completed the whole study. Six patients discontinued before 10 weeks and thirteen at 10 weeks or later, mainly because of side-effects (aggression, depressed mood, raised liver enzymes, thyroid hormones, diastolic blood<br/><br>
pressure), decreasing efficacy or non-compliance. <br/><br>
<br/><br>
Conclusion: <br/><br>
Fifty percent responded to treatment, but only one patient (5%) felt sufficient improvement to continue for one year. Dosage may have been too low, and baseline impairment too high, for atomoxetine to have sufficient effect on ADHD symptoms in our group of adults. The majority had few side-effects, but several terminated treatment because of adverse effects.},
  author       = {Johnson, Mats and Cederlund, Mats and Råstam, Maria and Areskoug, Björn and Gillberg, Christopher},
  issn         = {1557-1246},
  keyword      = {long-term trial,adults,atomoxetine,ADHD},
  language     = {eng},
  number       = {5},
  pages        = {45--539},
  publisher    = {ARRAY(0xac16298)},
  series       = {Journal of Attention Disorders},
  title        = {Open-Label Trial of Atomoxetine Hydrochloride in Adults With ADHD},
  url          = {http://dx.doi.org/10.1177/1087054709332372},
  volume       = {13},
  year         = {2010},
}